Cargando…
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors
Although many potent drugs have been used for cytokine storm, mortality is high for patients with coronavirus disease-2019 (COVID-19), which is followed up in the intensive care unit. Interferons (IFNs) are the major cytokines of the antiviral defense system released from many cell types. However, I...
Autores principales: | Cure, Erkan, Kucuk, Adem, Cure, Medine Cumhur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262416/ https://www.ncbi.nlm.nih.gov/pubmed/34169908 http://dx.doi.org/10.4103/ijp.IJP_615_20 |
Ejemplares similares
-
Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19)
por: Cure, Erkan, et al.
Publicado: (2020) -
NSAIDs may increase the risk of thrombosis and acute renal failure in patients with COVID-19 infection
por: Cumhur Cure, Medine, et al.
Publicado: (2020) -
Comment on “Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?”
por: Cure, Erkan, et al.
Publicado: (2020) -
Colchicine may not be effective in COVID-19 infection; it may even be harmful?
por: Cumhur Cure, Medine, et al.
Publicado: (2020) -
Can COVID-19 cause myalgia with a completely different mechanism? A hypothesis
por: Kucuk, Adem, et al.
Publicado: (2020)